STOCK TITAN

Nuvation Bio Inc - NUVB STOCK NEWS

Welcome to our dedicated news page for Nuvation Bio (Ticker: NUVB), a resource for investors and traders seeking the latest updates and insights on Nuvation Bio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nuvation Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nuvation Bio's position in the market.

Rhea-AI Summary
Nuvation Bio Inc. (NYSE: NUVB) will present updated data on taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology Annual Meeting. The Phase 2 TRUST-I study will showcase the efficacy and safety of taletrectinib in ROS1-positive non-small cell lung cancer patients in China. Presenter Wei Li, M.D., will discuss the findings on Saturday, June 1, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
conferences
-
Rhea-AI Summary
Nuvation Bio completes the acquisition of AnHeart Therapeutics, transforming into a late-stage global oncology company. Shareholders now own approximately 67% and 33% of NUVB, setting the stage for potential commercial success by 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.28%
Tags
-
Rhea-AI Summary
Nuvation Bio Inc. appoints Colleen Sjogren as Chief Commercial Officer, bringing nearly 30 years of biopharmaceutical experience. The company aims to become a commercial organization by the end of 2025 through the pending acquisition of AnHeart Therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.31%
Tags
management
Rhea-AI Summary
Nuvation Bio Inc. acquires AnHeart Therapeutics , transforming into a late-stage global oncology company with promising assets like taletrectinib and safusidenib. The all-stock transaction maintains strong cash balance, enabling development without raising capital. The Acquisition is expected to close in Q2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.6%
Tags
-
Rhea-AI Summary
Nuvation Bio Inc. (NYSE: NUVB) announces the dosing of the first patient in a Phase 1/2 study of NUV-1511, their first drug-drug conjugate (DDC) to enter the clinic. The study aims to establish the recommended Phase 2 dose for NUV-1511 and evaluate safety, tolerability, pharmacokinetic profile, and clinical activity in patients with various advanced solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.11%
Tags
-
Rhea-AI Summary
Nuvation Bio Inc. reports completion of Phase 1 monotherapy study of NUV-868, determination of MTD, ongoing Phase 1b studies with olaparib and enzalutamide. FDA clearance for NUV-1511 IND application. Strong financial position with $611.2 million in cash and marketable securities as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.25%
Tags
Rhea-AI Summary
Nuvation Bio Inc. (NYSE: NUVB) announced the appointment of Robert Mashal, M.D. to its Board of Directors. Dr. Mashal, a seasoned biotech industry veteran, will provide valuable insights to advance Nuvation's pipeline. His experience as an investor, operator, and medical oncologist makes him a valuable addition to the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.58%
Tags
management
-
Rhea-AI Summary
Nuvation Bio Inc. (NUVB) announced FDA clearance of its IND application for NUV-1511, the first clinical candidate from its novel drug-drug conjugate platform. The company anticipates initiating a Phase 1/2 clinical study of NUV-1511 in 1H 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.58%
Tags
-
Rhea-AI Summary
Nuvation Bio Inc. (NUVB) announces the resignation of Chief Financial Officer Jennifer Fox to pursue new opportunities. Ms. Fox seeks later stage development and commercial launch experience, leaving with high regard for the Company. Her resignation is effective November 27, 2023. Executive and finance team members will assume CFO duties and responsibilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.47%
Tags
none
Rhea-AI Summary
Nuvation Bio Inc. reports Q3 2023 financial results with cash, cash equivalents, and marketable securities of $619.3 million. Phase 1 monotherapy study of NUV-868 and Phase 1b study of NUV-868 in combination with olaparib or enzalutamide are ongoing. Expect to submit an IND for first Drug-Drug Conjugate (DDC) clinical candidate by year end 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.47%
Tags
Nuvation Bio Inc

NYSE:NUVB

NUVB Rankings

NUVB Stock Data

732.68M
138.87M
23.97%
55.01%
1.37%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
New York

About NUVB

nuvation bio is a biopharmaceutical company focused on revolutionizing cancer treatment by discovering, developing and delivering therapies that tackle some of the greatest needs in oncology. nuvation bio’s proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. nuvation bio was founded in 2018 by biopharma industry veteran david hung, m.d., who previously founded medivation, inc., which brought to patients one of the world’s leading prostate cancer medicines. nuvation bio has offices in new york and san francisco.